(D-Lys(nicotinoyl)1,β-(3-pyridyl)-Ala3,3,4-dichloro-D-Phe5,Asn6,D-Trp7·9,Nle11)-Substance P trifluoroacetate salt

Spantide II, an undecapeptide substance P (SP) analog, is a potent neurokinin-1 receptor (NK-1R) antagonist. Spantide II binds with NK-1R and blocks proinflammatory activities associated with SP. Spantide II can be used in the research of inflammatory skin disorders, such as psoriasis and contact dermatitis[1][2][3].

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Neuronal Signaling >> Neurokinin Receptor

Signaling Pathways >> GPCR/G Protein >> Neurokinin Receptor

NK1

[1]. Xu XJ, et al. Spantide II, a novel tachykinin antagonist, and galanin inhibit plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw. Neuroscience. 1991;42(3):731-7.  

[2]. Kikwai L, et al. In vitro and in vivo evaluation of topical formulations of spantide II. AAPS PharmSciTech. 2005 Oct 31;6(4):E565-72.  

[3]. Babu RJ, et al. Percutaneous absorption and anti-inflammatory effect of a substance P receptor antagonist: spantide II. Pharm Res. 2004 Jan;21(1):108-13.